Skip to content

A study to explore the role of inflammatory factors in different kinds of antidepressant's efficacy and recurrence prediction based on depression cohort

A study to explore the role of inflammatory factors in different kinds of antidepressant's efficacy and recurrence prediction based on depression cohort

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027424
Enrollment
Unknown
Registered
2019-11-12
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder

Interventions

Case series:Nil

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male or female outpatients aged at least 18 years and not more than 65 years; 2. Has a diagnosis of major depressive disorder by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria(comfimed by MINI); 3. Systemic anti-depressants treatment were not adopted during current episode, or has taken anti-depressants less than 7 days in last 14 days; 4. Total scord of QIDS-SR16 >=11 and HAMD-17 >=20 at enrolment in open-label preliminary phase; 5. Has at least primary school education and can understand the scales; 6. Prepareing to use escitalopram or venlafaxine sustained release tablets or mirtazapine; 7. Signed an informed consent form by patients.

Exclusion criteria

Exclusion criteria: 1. History of manic episode hypomanic episode; 2. History of bipolar, schizophrenia, schizoaffective disorder, or other psychotic disorders; 3. History of drug and alcohol dependence or acute intoxication; 4. Women in pregnancy or lactation; 5. Significant risk of suicidal behaviors, HAMD-17 Item 3(suicide) score >=3; 6. Current clinically significant disease.

Design outcomes

Primary

MeasureTime frame
effective rate;Inflammatory factor;

Secondary

MeasureTime frame
resting state functional magnetic resonance imaging, rs-fMRI;

Countries

China

Contacts

Public ContactGang Wang

Beijing Anding Hospital, Capital Medical University

gangwangdoc@vip.163.com+86 13911695727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026